The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations.
Akito Hata
No relevant relationships to disclose
Nobuyuki Katakami
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca; Chugai Pharma
Hiroshige Yoshioka
Honoraria - AstraZeneca; Chugai Pharma
Jumpei Takeshita
No relevant relationships to disclose
Kosuke Tanaka
No relevant relationships to disclose
Shigeki Nanjo
No relevant relationships to disclose
Reiko Kaji
No relevant relationships to disclose
Shiro Fujita
No relevant relationships to disclose
Yukihiro Imai
No relevant relationships to disclose
Kazuya Monden
No relevant relationships to disclose
Takeshi Matsumoto
No relevant relationships to disclose
Kazuma Nagata
No relevant relationships to disclose
Kyoko Otsuka
No relevant relationships to disclose
Ryo Tachikawa
No relevant relationships to disclose
Keisuke Tomii
No relevant relationships to disclose
Kei Kunimasa
No relevant relationships to disclose
Masahiro Iwasaku
No relevant relationships to disclose
Akihiro Nishiyama
No relevant relationships to disclose
Tadashi Ishida
No relevant relationships to disclose